Literature DB >> 22812695

Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera.

Nenghui Liu1, Changju Zhou, Jingfeng Zhao, Yuxiang Chen.   

Abstract

The purpose of this study was to establish tumor tissue specific delivery of let-7i miRNA to reverse paclitaxel-induced chemoresistance. A chimera that combines MUC1 aptamer and let-7i miRNA was tested in OVCAR-3 ovarian cancer cells. Results demonstrated that the chimera can specifically be delivered into OVCAR-3 cells and the released let-7i significantly sensitized the role of paclitaxel in inhibiting cell proliferation, inducing cell apoptosis, and decreasing long-term cell survival. The chimera achieved reversal of chemoresistance through downregulation of cyclin D1, cyclin D2, Dicer 1, and PGRMC1 expressions. Our study indicated that this MUC1/let-7i chimera can specifically reverse chemoresistance to paclitaxel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22812695     DOI: 10.3109/07357907.2012.707265

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  31 in total

1.  Progesterone receptor membrane component 1 deficiency attenuates growth while promoting chemosensitivity of human endometrial xenograft tumors.

Authors:  Anne M Friel; Ling Zhang; Cindy A Pru; Nicole C Clark; Melissa L McCallum; Leen J Blok; Toshi Shioda; John J Peluso; Bo R Rueda; James K Pru
Journal:  Cancer Lett       Date:  2014-10-07       Impact factor: 8.679

2.  Multifunctional aptamer-miRNA conjugates for targeted cancer therapy.

Authors:  Carla L Esposito; Laura Cerchia; Silvia Catuogno; Gennaro De Vita; Justin P Dassie; Gianluca Santamaria; Piotr Swiderski; Gerolama Condorelli; Paloma H Giangrande; Vittorio de Franciscis
Journal:  Mol Ther       Date:  2014-01-20       Impact factor: 11.454

3.  Expression of microRNA-30a-5p in drug-resistant and drug-sensitive ovarian cancer cell lines.

Authors:  Jin Liu; Xiaohua Wu; Hongmei Liu; Yijuan Liang; Xinping Gao; Zhihui Cai; Weiming Wang; Hui Zhang
Journal:  Oncol Lett       Date:  2016-07-08       Impact factor: 2.967

Review 4.  Bispecific therapeutic aptamers for targeted therapy of cancer: a review on cellular perspective.

Authors:  Somayeh Vandghanooni; Morteza Eskandani; Jaleh Barar; Yadollah Omidi
Journal:  J Mol Med (Berl)       Date:  2018-07-28       Impact factor: 4.599

Review 5.  Progress in microRNA delivery.

Authors:  Yu Zhang; Zaijie Wang; Richard A Gemeinhart
Journal:  J Control Release       Date:  2013-09-25       Impact factor: 9.776

6.  Advances in miRNA-Mediated Mucin Regulation.

Authors:  Shiv Ram Krishn; Surinder K Batra; Sukhwinder Kaur
Journal:  Curr Pharmacol Rep       Date:  2015-01-15

Review 7.  MicroRNAs in gynecological cancers: Small molecules with big implications.

Authors:  Sanjeev K Srivastava; Aamir Ahmad; Haseeb Zubair; Orlandric Miree; Seema Singh; Rodney P Rocconi; Jennifer Scalici; Ajay P Singh
Journal:  Cancer Lett       Date:  2017-05-24       Impact factor: 8.679

8.  Direct validation of aptamers as powerful tools to image solid tumor.

Authors:  Olivier Martínez; Elisabeth Bellard; Muriel Golzio; Saad Mechiche-Alami; Marie-Pierre Rols; Justin Teissié; Vincent Ecochard; Laurent Paquereau
Journal:  Nucleic Acid Ther       Date:  2014-02-03       Impact factor: 5.486

9.  miR-761 inhibits tumor progression by targeting MSI1 in ovarian carcinoma.

Authors:  Can Shi; Zhenyu Zhang
Journal:  Tumour Biol       Date:  2015-11-12

Review 10.  Modulation of chemoresponsiveness to platinum-based agents by microRNAs in cancer.

Authors:  Xin Yu; Heyi Zheng; Matthew Tv Chan; William Kk Wu
Journal:  Am J Cancer Res       Date:  2017-09-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.